Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients.

Felix AS, Edwards RP, Stone RA, Chivukula M, Parwani AV, Bowser R, Linkov F, Weissfeld JL.

Br J Cancer. 2012 Jun 5;106(12):2004-9. doi: 10.1038/bjc.2012.200. Epub 2012 May 22.

2.

[mRNA expression of basic fibroblast growth factor and hepatocyte growth factor in gastric carcinoma and significance thereof].

Ru GQ, Zhao ZS, Tang QL, Xu WJ.

Zhonghua Yi Xue Za Zhi. 2008 Jul 29;88(29):2030-5. Chinese.

PMID:
19080429
3.
4.

Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer.

Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ.

Anat Rec (Hoboken). 2009 Aug;292(8):1114-21. doi: 10.1002/ar.20934.

5.

Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A.

Eur Urol. 2009 Nov;56(5):837-45. doi: 10.1016/j.eururo.2008.10.003. Epub 2008 Oct 11.

PMID:
18945538
6.

Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma.

Wagatsuma S, Konno R, Sato S, Yajima A.

Cancer. 1998 Feb 1;82(3):520-30.

PMID:
9452270
7.

Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.

Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M.

Hum Pathol. 2010 Nov;41(11):1516-29. doi: 10.1016/j.humpath.2010.05.006. Epub 2010 Aug 30.

PMID:
20800872
8.

The prognostic significance of tumour-stroma ratio in endometrial carcinoma.

Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, Cummings M.

BMC Cancer. 2015 Dec 16;15:955. doi: 10.1186/s12885-015-1981-7.

9.

Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.

Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y.

J Urol. 2010 May;183(5):1744-50. doi: 10.1016/j.juro.2010.01.018. Epub 2010 Mar 17.

PMID:
20299037
10.

Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer.

Yoshida S, Harada T, Iwabe T, Taniguchi F, Fujii A, Sakamoto Y, Yamauchi N, Shiota G, Terakawa N.

J Clin Endocrinol Metab. 2002 May;87(5):2376-83.

PMID:
11994390
11.

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.

Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM.

Gynecol Oncol. 2011 Apr;121(1):218-23. doi: 10.1016/j.ygyno.2010.11.031. Epub 2010 Dec 17.

PMID:
21168200
12.

Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.

Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ.

Gynecol Oncol. 2013 Mar;128(3):454-60. doi: 10.1016/j.ygyno.2012.11.035. Epub 2012 Nov 30.

PMID:
23206584
13.

Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, Linkov F.

Int J Gynecol Cancer. 2011 Jul;21(5):877-84. doi: 10.1097/IGC.0b013e31821a62dd.

14.

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.

Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T.

Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8.

PMID:
15019676
15.

[Relationship between microsatellite instability and hepatocyte growth factor expression and their prognostic significance in colorectal cancer].

Yang G, Zheng HX, Wu LN, Wan HL, Li N, Yang GC, Liang JF.

Zhonghua Zhong Liu Za Zhi. 2016 Apr;38(4):283-8. doi: 10.3760/cma.j.issn.0253-3766.2016.04.008. Chinese.

PMID:
27087375
16.

Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.

Jiang XF, Tang QL, Shen XM, Li HG, Chen LH, Wang XY, Luo X, Lin ZQ, Jiang GY.

Pathol Res Pract. 2012 Dec 15;208(12):730-5. doi: 10.1016/j.prp.2012.09.011. Epub 2012 Nov 2.

PMID:
23122929
17.

The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.

Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W.

Dig Liver Dis. 2006 Jul;38(7):490-7. Epub 2006 Apr 14.

PMID:
16627020
18.

The clinical significance of hepatocyte growth factor for non-small cell lung cancer.

Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ.

Ann Thorac Surg. 1998 Dec;66(6):1915-8.

PMID:
9930468
19.

Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas.

Baykal C, Ayhan A, Al A, Yüce K, Ayhan A.

Gynecol Oncol. 2003 Feb;88(2):123-9.

PMID:
12586590
20.

Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis.

Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M.

Lung Cancer. 2012 Feb;75(2):181-8. doi: 10.1016/j.lungcan.2011.07.008. Epub 2011 Aug 27.

PMID:
21872356

Supplemental Content

Support Center